Author

K. Muthuraman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

E. Rujas· 2 shared J.-P. Julien· 2 shared A. C. Adams· 1 shared A. Jetha· 1 shared A. Pustilnik· 1 shared A. Sultana· 1 shared B. A. Heinz· 1 shared B. E. Jones· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

E. Rujas

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Antibody avidity and multi-specificity combined to confer protection against SARS-CoV-2 and resilience against viral escape

C. Burn Aschner, K. Muthuraman, I. Kucharska, H. Cui, K. Prieto, M. S. Nair, M. Wang, Y. Huang, N. Christie-Holmes, B. Poon, J. Lam, A. Sultana, R. Kozak, S. Mubareka, J. L. Rubinstein, , J.-P. Julien

This study develops a multimeric antibody platform (Multabody) that enhances neutralization potency and breadth against SARS-CoV-2 and its variants through avidity and multi-specificity.

bioRxiv · Oct 23, 2022 · PreprintImmunology

Dual inhibition of vacuolar ATPase and TMPRSS2 is required for complete blockade of SARS-CoV-2 entry into cells

S. Icho, E. Rujas, K. Muthuraman, J. Tam, H. Liang, S. Harms, M. Liao, D. Falzarano, J.-P. Julien, R. Melnyk

This study identifies bafilomycin A1 as a potent inhibitor of SARS-CoV-2 entry via the endosomal route and shows synergy with TMPRSS2 inhibitors.

bioRxiv · Mar 11, 2022Cell Biology

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

B. E. Jones, P. L. Brown-Augsburger, K. S. Corbett, K. Westendorf, J. Davies, T. P. Cujec, C. M. Wiethoff, J. L. Blackbourne, B. A. Heinz, D. Foster, R. E. Higgs, D. Balasubramaniam, L. Wang, R. Bidshahri, L. Kraft, , M. de Vries

LY-CoV555, an anti-spike antibody from a convalescent COVID-19 patient, neutralizes SARS-CoV-2 and protects non-human primates against infection.

bioRxiv · Sep 30, 2020Immunology